Northwestern Mutual Wealth Management Co. raised its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 3.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,885 shares of the biopharmaceutical company’s stock after acquiring an additional 1,615 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Lexicon Pharmaceuticals were worth $705,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LXRX. USS Investment Management Ltd bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $57,705,000. Pinnacle Associates Ltd. bought a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at about $11,759,000. Vanguard Group Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 16.3% in the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after buying an additional 585,222 shares during the period. Highbridge Capital Management LLC bought a new stake in shares of Lexicon Pharmaceuticals in the first quarter valued at about $7,813,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Lexicon Pharmaceuticals in the first quarter valued at about $5,485,000.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/14/lexicon-pharmaceuticals-inc-lxrx-holdings-raised-by-northwestern-mutual-wealth-management-co.html.

Several equities research analysts recently weighed in on LXRX shares. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Wedbush reiterated an “ourperform” rating and issued a $39.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, August 7th. BidaskClub cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Finally, ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $27.00.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) opened at 13.76 on Thursday. The company’s market cap is $1.45 billion. The firm’s 50-day moving average is $14.95 and its 200-day moving average is $15.39. Lexicon Pharmaceuticals, Inc. has a 52 week low of $12.93 and a 52 week high of $19.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12. The firm had revenue of $12.00 million during the quarter, compared to the consensus estimate of $18.34 million. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The business’s revenue for the quarter was down 40.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.37) EPS. On average, analysts expect that Lexicon Pharmaceuticals, Inc. will post ($1.45) EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.